Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Junshi Biosciences Secures Global Exclusive Rights to CAS’s Tetravalent Recombinant Dengue Vaccine in Landmark Licensing Deal

Fineline Cube Jun 12, 2026
Company Deals

Kelun-Biotech Receives USD 89 Million Settlement Payment from Medilink Therapeutics Over ADC Pipeline Out-Licensing Dispute

Fineline Cube Jun 12, 2026
Company Deals

HJ Science Launches HK$1.11 Billion IPO on Hong Kong Exchange to Advance Clinical-Stage Pipeline in Autoimmune, Metabolic, and Oncology Therapies

Fineline Cube Jun 12, 2026
Company Deals

Cascade Pharmaceuticals Secures RMB 318 Million Series D Financing to Advance Bile Acid Metabolism Pipeline

Fineline Cube Jun 12, 2026
Company Deals

QuantumPharm (XtalPi) Secures $400 Million AI-Driven Partnership for Best-in-Class GPCR-Targeting Oral Small-Molecule Drug

Fineline Cube Jun 11, 2026
Policy / Regulatory

China’s CDE Releases 107th Batch of Reference Preparations for Generic Drug Consistency Evaluation with 17 New Drugs Added

Fineline Cube Jun 12, 2026
Company Drug

Shouyao Holdings Secures NMPA Approval for Second-Generation ALK Inhibitor CT-707 as First-Line Treatment for ALK-Positive NSCLC

Fineline Cube Jun 12, 2026
Company Drug

Createrna’s MY008211A Becomes China’s First Home-Grown Oral CFB Inhibitor Approved for Paroxysmal Nocturnal Hemoglobinuria

Fineline Cube Jun 12, 2026
Company

BeiGene Announces Plans to Relocate Headquarters to Switzerland from Cayman Islands

Fineline Cube May 15, 2025

BeiGene, Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235), the China-based oncology company that has proposed...

Company Drug

Chengdu Kanghong’s KH607 Approved for Clinical Trials in Postpartum Depression

Fineline Cube May 15, 2025

China-based Chengdu Kanghong Pharmaceutical Group Co., Ltd. (SHE: 002773) has announced that it has received...

Medical Device Policy / Regulatory

NMPA Releases Updated List of Medical Devices Exempted from Clinical Evaluation

Fineline Cube May 15, 2025

The National Medical Products Administration (NMPA) has released the latest version of the “List of...

Company Drug

Boehringer Ingelheim’s Nerandomilast Filing Accepted for Review in Progressive Pulmonary Fibrosis

Fineline Cube May 15, 2025

Boehringer Ingelheim announced that the Center for Drug Evaluation (CDE) of China’s National Medical Products...

Company Drug

Novartis’ Kisqali Receives NMPA Approval for High-Risk Early Breast Cancer

Fineline Cube May 15, 2025

Switzerland-based Novartis (NYSE: NVS) announced this week that it has received another indication approval from...

Company Deals

MGI Tech Partners with Genoks to Enhance Clinical Testing Services in Türkiye

Fineline Cube May 15, 2025

China-based gene sequencing specialist MGI Tech Co., Ltd. (SHA: 688114) has entered into a strategic...

Company Deals

Jiangsu Hengrui Pharmaceuticals Launches Hong Kong IPO of H-Shares

Fineline Cube May 15, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has officially launched an initial public offering...

Company Deals

CSPC Pharma Licenses Irinotecan Liposome Injection to Cipla for US Market

Fineline Cube May 15, 2025

China-based CSPC Pharmaceutical Group Ltd. (HKG: 1093) has entered into a licensing agreement with India-headquartered...

Company Drug

WuHan Hamilton Biotech’s HUC-MSCs Product Approved for Clinical Trials in Premature Ovarian Failure

Fineline Cube May 15, 2025

China-based WuHan Hamilton Biotechnology Co., Ltd. has announced receiving clinical trial approval from the National...

Others

AbbVie Pays $335 Million Upfront to ADARx for Next-Gen siRNA Therapeutics

Fineline Cube May 15, 2025

US-based pharma giant AbbVie (NYSE: ABBV) has entered into a significant collaboration with ADARx Pharmaceuticals,...

Company Medical Device

Roche’s VENTANA MET (SP44) RxDx Assay Gains FDA Approval for NSQ-NSCLC Patients

Fineline Cube May 15, 2025

Swiss giant Roche (SWX: ROG, OTCMKTS: RHHBY) announced that the FDA has approved the VENTANA®...

Company Deals

Novo Nordisk and Septerna Ink $2.2 Billion Deal for GPCR Drug Discovery

Fineline Cube May 15, 2025

Denmark-based Novo Nordisk (NYSE: NVO, CPH: NOVO-B) and Septerna, Inc. (NASDAQ: SEPN) announced an exclusive...

Company

Sanofi Announces $20 Billion Investment in US R&D and Manufacturing by 2030

Fineline Cube May 15, 2025

French pharmaceutical giant Sanofi (NASDAQ: SNY) has announced its intention to invest at least $20...

Company Deals

GSK Signs Deal to Acquire Boston Pharmaceuticals’ Efimosfermin Alpha

Fineline Cube May 14, 2025

UK-based pharmaceutical giant GlaxoSmithKline (GSK, NYSE: GSK) has entered into an agreement to acquire BP...

Company Deals

Acchrom Technologies Secures Pre-Series B Funding to Expand Chromatography Solutions

Fineline Cube May 14, 2025

Beijing-based Acchrom Technologies Co., Ltd., a specialist in chromatography, has reportedly secured over RMB 100...

Company Deals

Ningbo Jansen Files STAR IPO for MRI Technology Expansion

Fineline Cube May 14, 2025

China-based Ningbo Jansen NMR Technology Co., Ltd. announced that its initial public offering (IPO) filing...

Company Drug Medical Device

China’s Q1 2025 Pharmaceutical Exports Rise 4.39% Despite Import Decline

Fineline Cube May 14, 2025

The China Chamber of Commerce for Import and Export of Medicines and Health Products (CCCMHPIE)...

Company Deals

Porton Pharma Collaborates with Henan Hualong for MATC Therapy Development

Fineline Cube May 14, 2025

China-based Contract Development and Manufacturing Organization (CDMO) Porton Pharma Solutions Ltd has entered into a...

Company

Bayer Reports Flat Q1 Revenue amid Crop Science Decline

Fineline Cube May 14, 2025

German pharmaceutical and chemical giant Bayer (ETR: BAYN) released its Q1 2025 financial report, recording...

Company Drug

Medilink Therapeutics Gains FDA IND Approval for VEGF-Targeted ADC YL242

Fineline Cube May 14, 2025

Suzhou-based Medilink Therapeutics announced that it has received Investigational New Drug (IND) approval from the...

Posts pagination

1 … 178 179 180 … 682

Recent updates

  • Junshi Biosciences Secures Global Exclusive Rights to CAS’s Tetravalent Recombinant Dengue Vaccine in Landmark Licensing Deal
  • Shouyao Holdings Secures NMPA Approval for Second-Generation ALK Inhibitor CT-707 as First-Line Treatment for ALK-Positive NSCLC
  • Createrna’s MY008211A Becomes China’s First Home-Grown Oral CFB Inhibitor Approved for Paroxysmal Nocturnal Hemoglobinuria
  • China’s CDE Releases 107th Batch of Reference Preparations for Generic Drug Consistency Evaluation with 17 New Drugs Added
  • Takeda’s Zasocitinib Demonstrates Superior Efficacy Over Deucravacitinib in Phase III Psoriasis Trial with 35% PASI 100 Response Rate
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Junshi Biosciences Secures Global Exclusive Rights to CAS’s Tetravalent Recombinant Dengue Vaccine in Landmark Licensing Deal

Company Drug

Shouyao Holdings Secures NMPA Approval for Second-Generation ALK Inhibitor CT-707 as First-Line Treatment for ALK-Positive NSCLC

Company Drug

Createrna’s MY008211A Becomes China’s First Home-Grown Oral CFB Inhibitor Approved for Paroxysmal Nocturnal Hemoglobinuria

Policy / Regulatory

China’s CDE Releases 107th Batch of Reference Preparations for Generic Drug Consistency Evaluation with 17 New Drugs Added

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.